What question did this study set out to answer?

The aim is to explore physician perspectives on the use of pembrolizumab for patients with high-risk early-stage triple-negative breast cancer in clinical settings.

July 5, 2026Future Oncology

Physician perspectives on the decision-making process for patients with high-risk early-stage triple-negative breast cancer in a community oncology setting

View Full Paper

Ask AI

Bookmark

The aim is to explore physician perspectives on the use of pembrolizumab for patients with high-risk early-stage triple-negative breast cancer in clinical settings.
Conducted a survey and focus group with eight physicians from the US Oncology Network
Included analysis of survey responses and thematic analysis of focus group discussions
Participants comprised six medical oncologists and two breast surgeons.
Pembrolizumab is widely adopted as the standard treatment for high-risk, early-stage triple-negative breast cancer.
Nonuse occurs rarely, generally due to contraindications or lack of medical oncology input after surgery referrals.
Management strategies for estrogen receptor-low/HER2-negative breast cancer mirror those of triple-negative breast cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Qualitative exploration reveals influential factors in treatment decision-making for triple-negative breast cancer patients.

Cite This Study

Haiderali et al. (2026) studied this question.

synapsesocial.com/papers/6a49f68df5d1d45b28800e2b https://doi.org/10.1080/14796694.2026.2693604

View Full Paper

Ask AI

Bookmark

Physician perspectives on the decision-making process for patients with high-risk early-stage triple-negative breast cancer in a community oncology setting

Key Points

Discussion

Implication

Cite This Study

Physician perspectives on the decision-making process for patients with high-risk early-stage triple-negative breast cancer in a community oncology setting

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider